

## Correction

### Bortezomib and docetaxel in pancreatic cancer

In the article on bortezomib and docetaxel in pancreatic cancer in the January 2004 issue (1), an error appeared in the controls for Fig. 3A. These errors do not affect the overall conclusions. The correct Fig. 3A appears below.




Figure 3.

#### Reference

1. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. *Mol Cancer Ther* 2004;3: 59 – 70.